- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Lupin unveils Mirabegron ER tablets in US
Mumbai: Global pharma major Lupin Limited has announced the launch of Mirabegron Extended-Release Tablets, 25 mg, in the United States, after having received an approval from the United States Food and Drug Administration (U.S. FDA).Mirabegron Extended-Release Tablets, 25 mg is a generic equivalent of Myrbetriq Extended-Release Tablets, 25 mg of Astellas Pharma Global...
Mumbai: Global pharma major Lupin Limited has announced the launch of Mirabegron Extended-Release Tablets, 25 mg, in the United States, after having received an approval from the United States Food and Drug Administration (U.S. FDA).
Mirabegron Extended-Release Tablets, 25 mg is a generic equivalent of Myrbetriq Extended-Release Tablets, 25 mg of Astellas Pharma Global Development, Inc.
Mirabegron Extended-Release Tablets, 25 mg had estimated annual sales of USD 1,019 million in the U.S. (IQVIA MAT February 2024).
Read also: Lupin unveils first generic version of Oracea in US
Ruchika Sharma joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751